When.com Web Search

  1. Ads

    related to: abiraterone acetate survival rate

Search results

  1. Results From The WOW.Com Content Network
  2. Abiraterone acetate - Wikipedia

    en.wikipedia.org/wiki/Abiraterone_acetate

    [41] [42] The FDA press release made reference to a phase III clinical trial in which abiraterone acetate use was associated with a median survival of 14.8 months versus 10.9 months with placebo; the study was stopped early because of the successful outcome. [43] Abiraterone acetate was also licensed by the European Medicines Agency. [44]

  3. Niraparib/abiraterone acetate - Wikipedia

    en.wikipedia.org/wiki/Niraparib/abiraterone_acetate

    Niraparib/abiraterone acetate, sold under the brand name Akeega, is a fixed-dose combination anti-cancer medication used for the treatment of prostate cancer. [2] It contains niraparib , a poly (ADP-ribose) polymerase (PARP) inhibitor (antineoplastic agent), and abiraterone acetate , a CYP17 inhibitor (hormone antagonist).

  4. Prostate cancer - Wikipedia

    en.wikipedia.org/wiki/Prostate_cancer

    Five-year survival rates range from 30–99%, depending on stage. [1] ... as well as the testosterone production inhibitor abiraterone acetate. ...

  5. Comparison of bicalutamide with other antiandrogens

    en.wikipedia.org/wiki/Comparison_of_bicalutamide...

    Another large study reported a rate of impotence of only 9.3% with bicalutamide relative to 6.5% for standard care (the controls), a rate of decreased libido of only 3.6% with bicalutamide relative to 1.2% for standard care, and a rate of 9.2% with bicalutamide for hot flashes relative to 5.4% for standard care. [125]

  6. Androgen deprivation therapy - Wikipedia

    en.wikipedia.org/wiki/Androgen_deprivation_therapy

    New antiandrogens that target testosterone synthesis (abiraterone acetate and seviteronel) or AR nuclear translocation (enzalutamide, apalutamide, and darolutamide), as well as combined therapies have been recently developed and may function to better target androgen-responsive cells in combination with ADT. [11]

  7. Δ4-Abiraterone - Wikipedia

    en.wikipedia.org/wiki/Δ4-Abiraterone

    Δ 4-Abiraterone (D4A; code name CB-7627), also known as 17-(3-pyridyl)androsta-4,16-dien-3-one, is a steroidogenesis inhibitor and active metabolite of abiraterone acetate, a drug which is used in the treatment of prostate cancer and is itself a prodrug of abiraterone (another active metabolite of abiraterone acetate). [1]